Blood donor, component, and recipient‐specific factors associated with venous thromboembolism in transfused hospitalized adult patients: Data from the recipient epidemiology and donor evaluation Study‐III (REDS‐III)

Abstract

Objective: Growing evidence suggests multiple pathophysiological mechanisms linking red blood cells (RBC) transfusions to thrombosis. This study examined blood donor, component, and recipient factors which may be associated with thromboembolic outcomes following RBC transfusion. Methods: We utilized the Recipient Epidemiology Donor Evaluation Study-III (REDS-III) database on patients transfused in 12 hospitals between 2013-2016. Stratified Cox proportional hazards regression models with time-dependent exposures were used to examine associations of donor and component modification characteristics on venous thromboembolism (VTE) in patients transfused RBC units.Results: 59,603 patients were transfused 229,500 RBC units during 79,298 hospitalizations with post-transfusion VTE occurring in 1869 (2.4%) of patients. In

Transforming research to improve therapies for trauma in the twenty-first century

“…Patients who received fresh RBCs (≤ 7 days of storage) prepared by a whole blood filtration, top / top manufacturing method had a higher risk of in-hospital mortality than those transfused with mid-age RBCs (stored 8–35 days) prepared by the red cell filtration (top/bottom) method. Similarly, RBC component-specific factors such as additive solution and collection method have been associated with differences in post-transfusion hemoglobin increments [ 38 ] and venous thromboembolism [ 39 ]. These works suggest that adverse transfusion outcomes might be reduced by making changes to blood processing methods and inventory management practices.…”

“…Up to 30% of survivors of the acute phase of severe trauma have persistent disability and reduced quality of life [ 39 ]. It is recognized that the persistent inflammation immunosuppressive catabolism syndrome (PICS) is associated with ongoing protein catabolism with loss of functional recovery, as well as with immune suppression, including a reduced generation of cytokines, loss of monocyte-macrophage function, and a reduction in the number and function of effector T cells.…”

Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS‐CoV‐2 infection and vaccination

“…The incidence of arterial and venous thromboses after plasma or platelet transfusion was defined using the combination of diagnosis codes and timing of new anticoagulant administration following transfusion. 26,27 We categorized the maximal level of respiratory support using mutually exclusive, hierarchical categories (room air, nasal cannula, high flow oxygen, noninvasive ventilation, and invasive ventilation). Maximal level of respiratory support was assessed prior to index transfusion and daily thereafter.…”